Glyxambi (Empagliflozin + Linagliptin) 10 mg/5 mg
Glyxambi (Empagliflozin 10 mg / Linagliptin 5 mg) is a premium fixed-dose combination therapy for Type 2 Diabetes.
Manufacturer: Boehringer Ingelheim (Germany). This medication combines two potent antidiabetic agents in a single pill to provide superior glycemic control compared to monotherapy.
Mechanism of Action ("Dual Pathway Control"):
- Empagliflozin (SGLT2 Inhibitor): Removes excess glucose from the body through urine by preventing the kidneys from reabsorbing it.
- Linagliptin (DPP-4 Inhibitor): Increases the levels of hormones that stimulate the pancreas to produce insulin after meals and signals the liver to produce less sugar.
β Key Benefit: Effective blood sugar reduction, potential weight loss, and cardiovascular benefits associated with Empagliflozin.
Indicated for adults with:
- π¬ Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control.
- Suitable for patients inadequately controlled on Metformin or those already treated with Empagliflozin and Linagliptin separately.
Packaging: Film-coated tablets (10 mg / 5 mg).
β οΈ DOSAGE & ADMINISTRATION:
- π Standard Dose: One tablet taken once daily.
- β° Timing: Recommended to be taken in the morning, with or without food.
- π§ Hydration: Drink plenty of water throughout the day to prevent dehydration.
- π Type 1 Diabetes Mellitus.
- Diabetic Ketoacidosis (DKA).
- Severe renal impairment (eGFR < 30 mL/min).
- Pregnancy and breastfeeding.
Specific side effects related to mechanism of action:
- π» Genital Infections: Yeast infections (Candida) in both men and women due to glycosuria (sugar in urine). Good hygiene is essential.
- π§ Dehydration: Increased urination and thirst.
- π Hypoglycemia: Low risk alone, but possible if combined with Insulin or Sulfonylureas.
- Urinary Tract Infections (UTIs).
What Customers Say
No reviews yet
Your review can be the first!